Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deerfield To Go As Takeda Plans Realignment Of Post-Shire US Ops

Executive Summary

Takeda is to close down and relocate one of its main US sites, with unspecified job losses, as it plans post-Shire restructuring, while in Japan vocal opposition to the acquisition rises.

You may also be interested in...



Hypera Pays $825m For Takeda LatAm Portfolio

Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.

More Divestments In Store As Takeda Digests Shire, Faces Expiries

Takeda remains committed to meeting its post-Shire divestment target, as it faces up to $2bn in at-risk revenues from expiries and seeks additional cost synergies. 

Shire Snags EU Okay For Von Willebrand Drug Veyvondi

Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel